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Informal Formalities

To Patent or Not To Patent, That is The Question:
Embryonic Stem Cell Patents Rejected in Europe
by Amer Raja
The following blog post was published on www.ipbrief.net on October 29, 2011.
Recently, the European Court of Justice was
asked to determine the patentability of stem-cell
products derived from human embryos. While the
question submitted to the Advocate General was not
as straightforward, both the Advocate General and the
Court seemed to have little trouble in taking a position
in this case. At the heart of this query was “whether
the human embryonic stem cells which serve as base
material for the patented processes constitute ‘embryos’
within the meaning
of Article 6(2)(c) of
the Directive.” The
Court’s decision in
this case, therefore,
also necessarily
addressed the
patentability of
“embryonic base
material” and
subsequent lines
of products arising
from base material.
The dispute
arose from Mr.
Oliver Brüstle’s
patent on “isolated
and purified neural
precursor cells
produced from
human embryonic
stem cells used to
treat neurological
diseases.” Mr.
Brüstle works at
the University of
Bonn in Germany as a Professor of Reconstructive
Neurobiology. Greenpeace, along with a number
of religious organizations, contested the patent and
sued for “ethical reasons,” to invalidate Mr. Brüstle’s
ownership rights in the patent. The patent was
declared “invalid insofar as it covers precursor cells
obtained from human embryonic stem cells,” by the
Federal Patent Court (Bundespatentgericht), and the
case was subsequently referred to the European Court
of Justice.

70

The issues that the European Court of Justice was
asked to determine largely arose from the European
Union’s approach to patentability and embryonic
research. The relevant legislation and treaty language
can be found in the German national law, TRIPS
article 27, CGEP articles 52(1) and 53, and Directive
98/44 with respect to article 6(2)(c). Of these sources
of law, the Court particularly focused on the directive
since the case turned on the definition of “embryo” and
the “dignity
and integrity”
of a person.
The Court’s
decision
was largely
centered on
the concepts
of ordre
public and
morality that
are included
in the laws
and treaties.
However,
since there
is some
question as
to whether
a stem cell
or purified
precursor
cell could be
considered
to be an
embryo,
the Court first attempted to define and interpret the
concept of human embryo with respect to article 6(2)
(c).
To give some context to the Court’s ruling, I
will briefly outline a few relevant points in stem cell
research. While there are a few different types of stem
cells, embryonic stem cells are probably the most
potent and controversial since production starts with
the fertilization of a human ovum (“egg”). Within a
few days after fertilization, a blastocyst is formed, which
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is comprised of a number of cells and regarded by a
number of scientists to be an early stage embryo. In
the interim period between fertilization and blastocyst
formation, the ovum (now a “zygote”) undergoes a
number of changes.
These changes include the formation of totipotent
cells (unspecialized cells which can form anything
in a human body) and eventually pluripotent cells
(which can form a number of things but within one of
three categories). Totipotent cells precede pluripotent
cells chronologically and denote different stages of
development. Therefore, the issue the Court had to
wrestle with determining the moment at which an
embryo could be regarded to exist, since it would be
protected by national law.
In the end, the Court determined that while the
pluripotent cells and blastocyst are more specialized in
the development of a human being, that totipotent cells
were also necessarily included in the definition of an
embryo. The Court stated that “[A]ny human ovum
must, as soon as fertilised, be regarded as a ‘human
embryo’ within the meaning and for the purposes of
the application of Article 6(2)(c) of the Directive, since
that fertilisation is such as to commence the process of
development of a human being.” This definition is also
meant to include traditionally and non-traditionally
matured ova, such as in parthenogenesis (maturation
of an ovum without fertilization). However, the Court
seems to have left open the question of whether a stem
cell obtained at the blastocyst stage is an embryo, which
may lead to further debate in the field. In addition
to its determination that an embryo exists once an
ovum is fertilized, the Court determined that scientific
research and industrial use of embryos cannot lead to
patents and further excluded any materials obtained
from the destruction or use of embryos as base material.
While the implications of this decision are not
entirely clear at this point, Mr. Brüstle and a number
of other scientists have articulated that this decision
comes as a huge blow to the scientific community.
The scientists feel that this decision will serve as a
huge setback in the development of stem cell products
and may result in a greater advantage for their Asian
counterparts. Greenpeace, the Catholic Church, and
a number of religious organizations, however, feel that
this decision comes as “a victory for human dignity.”
However, Mr. Julian Hitchcock, a lawyer with Field
Fisher Waterhouse LLP also voiced his opinion that
this decision may not actually be too detrimental to
stem cell research; it could very well provide scientists
and researchers with more freedom to not “worry about
infringing someone else’s patent.” Furthermore, he
points out that “While the ruling restricts patentability
of such inventions, it doesn’t in any way restrict the use

of embryonic stem cells.”
As a result the Court’s decision may not really
do much at all in the way of discouraging stem cell
research – it may very well promote it. While in the
United States we have the Bayh-Dole act to promote
non-commercial research which can later become
commercialized; embryonic stem cell products could
very well start as non-commercial ventures in Europe
and later lead to greater developments that may be
nevertheless be patentable as well. The incentive in
obtaining a patent and conducting a research may
merely be delayed as opposed to entirely eliminated.
Furthermore, some practitioners have even posited
the idea that researchers could depend on trade secrets
and regulatory procedures to sidestep the hurdle.
Lastly, the Court through its ruling has not foreclosed
all embryonic stem cell research as such. Scientists may
still be able to patent embryonic stem cell products by
establishing that a stem cell obtained at the blastocyst
should not be considered an embryo and therefore
could potentially be patentable subject matter. In sum,
the Court’s decision may provide very little guidance
at all, and certainly leaves open the question of how
to implement this new restriction on patentability;
it will certainly be interesting to see how scientists,
organizations, and Courts deal with this matter in the
coming months and years.
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